Form 4: Longeveron Inc. Grants Stock Options to Chief Scientific Officer Joshua Hare Following Shareholder Approval

Longeveron Inc. has granted 184,878 stock options to Chief Scientific Officer Joshua Hare, which will fully vest on July 1, 2025, following shareholder approval of an increase in shares available under the company's incentive plan.

Summary

• Joshua Hare, Chief Scientific Officer, Director, and 10% Owner of Longeveron Inc. (LGVN), was granted 184,878 stock options.
• The stock options have an exercise price of $1.49 per share.
• The grant was administratively made on April 11, 2025, contingent upon shareholder approval of an amendment to the Company's 2021 Incentive Award Plan to increase the number of shares available for awards.
• Shareholder approval for the plan amendment was obtained at the 2025 Annual Meeting of Stockholders held on June 13, 2025, satisfying the contingency.
• The options will 100% cliff vest on July 1, 2025.
• The options are set to expire on April 11, 2035.

Sentiment

Score: 6

Explanation: The document reports a standard executive compensation event (stock option grant) following a successful shareholder vote. While positive for executive alignment, it's a routine disclosure and doesn't indicate significant new operational or financial news, hence a neutral-to-slightly positive score.

Positives

• The grant of stock options to a key executive like the Chief Scientific Officer aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The option grant was contingent on shareholder approval of the incentive plan amendment, demonstrating adherence to corporate governance best practices regarding equity compensation.

Negatives

• The issuance of new stock options can lead to potential dilution for existing shareholders if the options are exercised, as it increases the total number of outstanding shares.

Risks

• The initial grant of the stock option was contingent on shareholder approval of an amendment to the Company's 2021 Incentive Award Plan, which was a risk until the approval was secured at the Annual Meeting on June 13, 2025. This contingency has now been satisfied.

Future Outlook

The stock options granted to Joshua Hare are set to 100% cliff vest on July 1, 2025, indicating a future milestone for this compensation. The options have a long expiration date of April 11, 2035, providing a long-term incentive.

Management Comments

• "The option will 100% cliff vest on July 1, 2025."
• "The option was administratively granted on April 11, 2025 contingent on the approval by the Company's stockholders of an amendment to the Company's 2021 Incentive Award Plan (as amended and restated to date) (the 'Plan') to increase the number of shares available for awards under the Plan at the 2025 Annual Meeting of Stockholders held on June 13, 2025 (the 'Annual Meeting')."
• "This stockholder approval contingency was satisfied upon approval of the share increase at the Annual Meeting."

Industry Context

The granting of stock options to key executives is a common practice across various industries, particularly in biotechnology and growth-oriented companies like Longeveron Inc. It serves as a non-cash compensation method designed to attract, retain, and motivate talent by aligning their financial interests with the long-term performance of the company and its share price. This specific filing reflects a routine executive compensation event following a corporate governance action (shareholder approval of an incentive plan amendment).

Comparison to Industry Standards

• The practice of granting stock options to Chief Scientific Officers is standard in the biotechnology and pharmaceutical sectors, where long-term R&D cycles necessitate retention and motivation of key scientific leadership.
• The exercise price of $1.49 per share is specific to Longeveron's current valuation and market conditions at the time of the administrative grant.
• The cliff vesting schedule (100% on July 1, 2025) is a common vesting structure, though graded vesting over several years is also prevalent.
• The 10-year expiration period (April 11, 2025, to April 11, 2035) is typical for executive stock options, providing a substantial window for the executive to realize value.
• Comparable companies in the small-cap biotech space often utilize similar equity incentive structures to compensate and retain executives, given the high-risk, high-reward nature of drug development. Specific comparable companies or projects are not detailed in this Form 4, as it focuses solely on the individual transaction.

Corporate Governance

Related Party Transactions

• The grant of stock options to Joshua Hare, who is the Chief Scientific Officer, Director, and a 10% Owner, constitutes a related party transaction as it involves compensation to a key executive and significant shareholder.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also potential for increased shareholder value if the options incentivize the executive to drive company performance and share price appreciation.
• Employees: The amendment to the Incentive Award Plan suggests the company has more shares available for awards, which could benefit other employees through future equity grants.

Next Steps

• The stock options will 100% cliff vest on July 1, 2025.
• Joshua Hare may exercise the options at any time after vesting and before the expiration date of April 11, 2035.

Key Dates

Keywords

Longeveron Inc., LGVN, Joshua Hare, Stock Options, SEC Form 4, Insider Transaction, Executive Compensation, Incentive Award Plan, Shareholder Approval, Biotechnology, Pharmaceuticals